(Q28274600)

Crossref

https://api.crossref.org/works/10.2165%2F11534420-000000000-00000

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11534420-000000000-00000

Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11534420-000000000-00000

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

12 December 2020

Managing depression as a chronic disease: a randomised trial of ongoing treatment in primary care

1 reference

12 December 2020

Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence.

1 reference

12 December 2020

Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system

1 reference

12 December 2020

Explaining patients' beliefs about the necessity and harmfulness of antidepressants

1 reference

12 December 2020

The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression.

1 reference

12 December 2020

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

1 reference

12 December 2020

Just keep taking the tablets: adherence to antidepressant treatment in older people in primary care

1 reference

12 December 2020

Impact of antidepressant drug adherence on comorbid medication use and resource utilization

1 reference

12 December 2020

Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.

1 reference

12 December 2020

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

1 reference

12 December 2020

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

1 reference

12 December 2020

Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events

1 reference

12 December 2020

The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France

1 reference

12 December 2020

Continuation and maintenance therapy in depression

1 reference

12 December 2020

Antidepressants and sexual dysfunction.

1 reference

12 December 2020

Adherence to antidepressant treatment among privately insured patients diagnosed with depression

1 reference

12 December 2020

The prevalence, clinical relevance, and public health significance of subthreshold depressions

1 reference

12 December 2020

Patients' early discontinuation of antidepressant prescriptions

1 reference

12 December 2020

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

1 reference

12 December 2020

A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.

1 reference

12 December 2020

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade

1 reference

12 December 2020

Nine-month predictors and outcomes of SSRI antidepressant continuation in primary care

1 reference

12 December 2020

Adherence to depression treatment in older adults: a narrative review.

1 reference

12 December 2020

Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial

1 reference

12 December 2020

Tolerability of modern antidepressants

1 reference

12 December 2020

Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine.

1 reference

12 December 2020

A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder

1 reference

12 December 2020

Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale.

1 reference

12 December 2020

Defining and measuring clinical effectiveness in the treatment of schizophrenia

1 reference

12 December 2020

The hospital anxiety and depression scale

1 reference

12 December 2020

Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder

1 reference

12 December 2020

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

1 reference

12 December 2020

Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture

1 reference

12 December 2020

Continuity of antidepressant treatment for adults with depression in the United States.

1 reference

12 December 2020

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

1 reference

12 December 2020

The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives

1 reference

12 December 2020

The medical management of depression

1 reference

12 December 2020

A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants

1 reference

12 December 2020

Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.

1 reference

12 December 2020

Provider and patient characteristics associated with antidepressant nonadherence: the impact of provider specialty.

1 reference

12 December 2020

A New Depression Scale Designed to be Sensitive to Change

1 reference

12 December 2020

Factor analysis of a sleep evaluation questionnaire

1 reference

12 December 2020

The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared

1 reference

12 December 2020

Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Escitalopram in the treatment of major depressive disorder: a meta-analysis

1 reference

12 December 2020

Prevalence of sexual dysfunction among newer antidepressants.

1 reference

12 December 2020

Pharmacotherapy to sustain the fully remitted state.

1 reference

12 December 2020

Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs

1 reference

12 December 2020

Discontinuing antidepressant treatment in major depression

1 reference

12 December 2020

The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder

1 reference

12 December 2020

A randomized trial of relapse prevention of depression in primary care

1 reference

12 December 2020

Characteristics and reasons associated with nonacceptance of selective serotonin-reuptake inhibitor treatment.

1 reference

12 December 2020

Tolerability and adherence issues in antidepressant therapy

1 reference

12 December 2020

Sleep cluster arousal analysis and treatment response to heterocyclic antidepressants in patients with major depression

1 reference

12 December 2020

What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?

1 reference

12 December 2020

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association

1 reference

12 December 2020

Sexual function during bupropion or paroxetine treatment of major depressive disorder.

1 reference

12 December 2020

Antidepressants and sleep: a qualitative review of the literature

1 reference

12 December 2020

Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents

1 reference

12 December 2020

Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review

1 reference

12 December 2020

Determinants of antidepressant treatment outcome

1 reference

12 December 2020

A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders.

1 reference

12 December 2020

Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine

1 reference

12 December 2020

Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report

1 reference

12 December 2020

Preventing recurrent depression: long-term treatment for major depressive disorder.

1 reference

12 December 2020

Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine

1 reference

12 December 2020

Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy--results from a managed care administrative claims database

1 reference

12 December 2020

Antidepressants and their effect on sleep

1 reference

12 December 2020

Discontinuation of use and switching of antidepressants: influence of patient-physician communication

1 reference

12 December 2020

Psychometric characteristics of the psychotropic-related sexual dysfunction questionnaire. Spanish work group for the study of psychotropic-related sexual dysfunctions

1 reference

12 December 2020

A rating scale for depression

1 reference

12 December 2020

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline

1 reference

12 December 2020

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

1 reference

12 December 2020

Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis.

1 reference

12 December 2020

Instability of symptoms in recurrent major depression: a prospective study

1 reference

12 December 2020

Antidepressant-induced sexual dysfunction

1 reference

12 December 2020

Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey.

1 reference

12 December 2020